{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:42:25Z","timestamp":1794440545379,"version":"4.9.1"},"reference-count":71,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>TP 53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most lethal malignancies, characterized by dismal outcomes with currently available therapies. Allogeneic hematopoietic cell transplantation (allo-HCT) is widely thought to be the only treatment option to offer durable disease control. However, outcomes with allo-HCT in this context are quite poor, calling into question the utility of transplantation. In this review, we summarize the latest data on allo-HCT outcomes in this subgroup, evaluating the limitations of available evidence; we review the molecular heterogeneity of this disease, delineating outcomes based on distinct biological features to aid in patient selection; and we critically examine whether allo-HCT should be routinely applied in this disease on the basis of currently available data. We propose that the exceptionally poor outcomes of patients with TP53-mutated MDS\/AML with biallelic loss and\/or adverse-risk cytogenetics should motivate randomized-controlled trials of HCT vs non-HCT to determine whether transplantation can prolong survival and\/or positively impact other clinically relevant outcomes such as patient-reported outcomes or healthcare resource utilization in this disease subset. Without dedicated prospective randomized trials, selecting who may actually derive benefit from allo-HCT for TP53-mutated MDS\/AML can be described as ambiguous guesswork and must be carefully contemplated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010417","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:13:17Z","timestamp":1702577597000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for\n                    <i>TP53-<\/i>\n                    mutated MDS\/AML"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-0878","authenticated-orcid":false,"given":"Mariam T.","family":"Nawas","sequence":"first","affiliation":[{"name":"Hematopoietic Cellular Therapy Program, Department of Medicine, The University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[{"name":"Hematopoietic Cellular Therapy Program, Department of Medicine, The University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"10","key":"2024021216544074500_bib1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"22","key":"2024021216544074500_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7471","key":"2024021216544074500_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"23","key":"2024021216544074500_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024021216544074500_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"2024021216544074500_bib6","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2024021216544074500_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7+ 3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (AML)","volume":"134","author":"Lindsley","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024021216544074500_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"6810","key":"2024021216544074500_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"7","key":"2024021216544074500_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"7","key":"2024021216544074500_bib11","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"22","key":"2024021216544074500_bib12","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024021216544074500_bib13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"2024021216544074500_bib14","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2024021216544074500_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024021216544074500_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024021216544074500_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"2024021216544074500_bib18","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024021216544074500_bib19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2021006580","article-title":"TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology","volume":"6","author":"Patel","year":"2022","journal-title":"Blood Adv"},{"issue":"29","key":"2024021216544074500_bib20","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024021216544074500_bib28","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"2024021216544074500_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol"},{"issue":"19","key":"2024021216544074500_bib23","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","article-title":"Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"123","author":"Middeke","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024021216544074500_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-017-0393-3","article-title":"Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"10","author":"Poir\u00e9","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2024021216544074500_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2024021216544074500_bib22","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2024021216544074500_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2016.07.018","article-title":"Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation","volume":"22","author":"Luskin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2024021216544074500_bib27","article-title":"Presence of TP53 mutation and monosomal karyotype predict the outcome of patients with acute myeloid leukemia in non-remission at allogeneic stem cell transplantation","volume":"132","author":"Najima","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2024021216544074500_bib29","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"2024021216544074500_bib30","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","article-title":"Genomic landscape of TP53-mutated myeloid malignancies","volume":"7","author":"Abel","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2024021216544074500_bib31","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.3390\/cancers15123210","article-title":"TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2024021216544074500_bib32","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","article-title":"Non-relapse mortality in TP53-mutated MDS\/AML - a multi-center collaborative study","volume":"138","author":"Byrne","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024021216544074500_bib33","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"issue":"30","key":"2024021216544074500_bib34","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"2024021216544074500_bib35","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study","author":"Versluis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2024021216544074500_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/PO.20.00355","article-title":"Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome","volume":"5","author":"Dillon","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"2024021216544074500_bib37","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024021216544074500_bib38","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"issue":"16 suppl","key":"2024021216544074500_bib39","article-title":"Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission","volume":"40","author":"Hourigan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024021216544074500_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024021216544074500_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-021-00479-3","article-title":"Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT","volume":"11","author":"Gilleece","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024021216544074500_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of &gt;\/=10% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024021216544074500_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024021216544074500_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"key":"2024021216544074500_bib45","doi-asserted-by":"crossref","first-page":"e17929","DOI":"10.7554\/eLife.17929","article-title":"TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions","volume":"5","author":"Shirole","year":"2016","journal-title":"Elife"},{"issue":"3","key":"2024021216544074500_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/cancers12030637","article-title":"Functional classification of TP53 mutations in acute myeloid leukemia","volume":"12","author":"Dutta","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"14","key":"2024021216544074500_bib47","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"63","author":"Shahzad","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2024021216544074500_bib48","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3324\/haematol.2017.172544","article-title":"Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status","volume":"102","author":"Aldoss","year":"2017","journal-title":"Haematologica"},{"issue":"21","key":"2024021216544074500_bib49","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024021216544074500_bib50","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024021216544074500_bib51","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024021216544074500_bib52","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"26","key":"2024021216544074500_bib53","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2024021216544074500_bib54","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/blood.V128.22.5844.5844","article-title":"Comorbidity from solid tumor or hematologic malignancy prior to allogeneic hematopoietic cell transplantation (HCT) may both increase non-relapse mortality","volume":"128","author":"D\u2019Angelo","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2024021216544074500_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.008","article-title":"TP53 mutations are associated with increased infections and reduced hematopoietic cell transplantation rates in myelodysplastic syndrome and acute myeloid leukemia","volume":"29","author":"Marvin-Peek","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024021216544074500_bib56","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2024021216544074500_bib57","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"2024021216544074500_bib58","article-title":"Gilead to discontinue phase 3 ENHANCE study of magrolimab plus azacitidine in higher-risk MDS. Press release","year":"21  2023","journal-title":"Gilead Sciences, Inc"},{"issue":"24","key":"2024021216544074500_bib59","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024021216544074500_bib60","article-title":"Gilead statement on the discontinuation of magrolimab study in AML with TP53 mutations","year":"26  2023","journal-title":"Gilead Sciences, Inc"},{"key":"2024021216544074500_bib61","article-title":"Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). Press release","year":"28  2020","journal-title":"Aprea Therapeutics"},{"issue":"10","key":"2024021216544074500_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax\u00a0+ azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"2024021216544074500_bib63","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","article-title":"Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation","volume":"7","author":"Short","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024021216544074500_bib64","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"issue":"suppl 1","key":"2024021216544074500_bib65","article-title":"Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation","volume":"134","author":"Chan","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2024021216544074500_bib66","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.bbmt.2019.12.075","article-title":"Long-term follow up of BMT CTN 0901, a randomized phase III trial comparing myeloablative (MAC) to reduced intensity conditioning (RIC) prior to hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplasia (MDS) (MAvRIC Trial)","volume":"26","author":"Scott","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024021216544074500_bib67","author":"Chokr","year":"16  2023"},{"issue":"34","key":"2024021216544074500_bib68","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024021216544074500_bib69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.2022016916","article-title":"An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML","volume":"141","author":"Sorror","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024021216544074500_bib70","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2024021216544074500_bib71","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.19055","article-title":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","volume":"203","author":"Elias","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/553\/2212765\/blooda_adv-2023-010417-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/553\/2212765\/blooda_adv-2023-010417-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T11:55:14Z","timestamp":1707738914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/3\/553\/506627\/Utility-or-futility-A-contemporary-approach-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010417","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}